TSHR and cyclic hematopoiesis: Our results showed that ~1.5% of studied CH-TD patients (N = 2/128) presented relevant FOXE1 (HC-266) and TSHR (HC-324) genotypes involving single-nucleotide, missense, and likely pathogenic classified variants (Table 1).